Journals / İnfeksiyon Dergisi / 2006 / Cilt: 20 - Sayı: 2

Decreased ciprofloxacin susceptibility in Salmonella enterica and nalidixic acid screening test

Salmonella enterica kökenlerinde azalmış siprofloksasin duyarlılığı ve nalidiksik asit tarama testi

Pages
103–106
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

To determine the reduced ciprofloxacin susceptibility, screening nalidixic acid resistance by disk diffusion was observed to be helpful.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Although the fluoroquinolones are the drugs of choice for invasive Salmonella infections, recently reduced ciprofloxacin susceptibility and therapeutic failures have been reported from many countries.
📊
Key Findings & Data:A total of 133 Salmonella enterica isolates collected between 1997-2005 were studied retrospectively.
💡
Conclusion & Impact:To determine the reduced ciprofloxacin susceptibility, screening nalidixic acid resistance by disk diffusion was observed to be helpful.
🔬Design:Research Article
📍Scope:2005 Verileri
⚙️Variables:Domain Parameters

Abstract

Although the fluoroquinolones are the drugs of choice for invasive Salmonella infections, recently reduced ciprofloxacin susceptibility and therapeutic failures have been reported from many countries. The purpose of this study was to determine reduced ciprofloxacin susceptibity among Salmonella enterica strains isolated in the routine laboratory. A total of 133 Salmonella enterica isolates collected between 1997-2005 were studied retrospectively. Nalidixic acid and ciprofloxacin susceptibilities were investigated by disk diffusion method according to the Clinical and Laboratory Standards Institute (CLSI) guidelines, also ciprofloxacin MIC values were determined by E-test. Reduced ciprofloxacin susceptibility was described as MIC values ? 1 µg/ml - ? 0.125 µg/ml. Ciprofloxacin MIC values of all 133 isolates were between 0.004-0.25 µg/ml. Twenty two isolates were classified as nalidixic acid resistant while the rest 111 were evaluated as sensitive. Ciprofloxacin MIC values of these 111 strains were ? 0.064 µg/ml and 22 isolates had MIC's between 0.125-0.25 µg/ml. Isolates for which the ciprofloxacin MICs were ? 0.064 µg/ml had inhibition zone diameters ? 33 mm for nalidixic acid whereas isolates showing decreased ciprofloxacin susceptibility had zone diameters of 25-32 mm. Among the S. enterica strains isolated in the laboratory 16.5% reduced ciprofloxacin susceptibility and nalidixic acid resistance were detected. To determine the reduced ciprofloxacin susceptibility, screening nalidixic acid resistance by disk diffusion was observed to be helpful.

Özet

İnvazif Salmonella infeksiyonlarında florokinolonların ilk seçilecek ilaçlar olmasına karşın son zamanlarda bir çok ülkeden azalmış duyarlılık ve buna bağlı tedavi başarısızlıkları bildirilmektedir. Bu çalışmanın amacı, Salmonella enterica kökenlerinde azalmış siprofloksasin duyarlılığını araştırmaktır. Çalışmada 1997-2005 yılları arasında soyutlanan 133 S. enterica kökeni retrospektif olarak incelendi. Nalidiksik asit ve siprofloksa-sin duyarlılıkları Clinical and Laboratory Standards Institute (CLSI) önerileri doğrultusunda disk difüzyon, siprofloksasin MİK değerleri ise E-test yöntemi ile belirlendi. Azalmış siprofloksasin duyarlılığı, siprofloksasin MİK ? 1 µg/ml - ? 0.125 µg/ml olması olarak tanımlandı. İncelenen kökenlerin siprofloksasin MİK değerleri 0.004-0.25 µg/ml. arasında bulundu. Kökenlerin 22'si nalidiksik aside dirençli, 111'i duyarlı idi. Duyarlı 111 kökenin siprofloksasin MİK'leri ? 0.064 µg/ml, dirençli 22 kökenin ise 0.125-0.25 µg/ml arasındaydı. Siprofloksasin MİK'leri ? 0.064 µg/ml olan kökenlerin disk difüzyon yöntemindeki nalidiksik asit inhibisyon zon çapları ? 33 mm bulundu. Siprofloksasine azalmış duyarlılık görülen kökenlerin zon çapları ise 25-32 mm arasında idi. Soyutlanan S. enterica kökenleri arasında %16.5 oranında azalmış siprofloksasasin duyarlılılığı belirlendi. Disk difüzyon yöntemi ile nalidiksik asit direnci araştırmanın azalmış siprofloksasin duyarlılığı olan kökenleri belirlemede yararlı olduğu görüldü.

🔖

Cite This Article

ÇİLLİ, F., AKINCI, P., TUNGER, A., AYDEMİR, Ş. (2022). Decreased ciprofloxacin susceptibility in Salmonella enterica and nalidixic acid screening test. İnfeksiyon Dergisi, Cilt: 20 - Sayı: 2, 103–106. https://ajindex.com/articles/546422

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Malorny B, Schroeter A, Reiner H. Incidence of quinolone resistance over the period 1986 to 1998 in veterinary Salmonella isolates from Germany. Antimicrob Agents Chemother 1999; 43: 2278-82
  2. Slinger R, Desjardins M, McCarthy AE, et al. Suboptimal clinical response to ciprofloxacin in patients with enteric fever due to Salmonella spp. with reduced fluoroquinolone susceptibility: a case series. BMJ Infectious Diseases 2004; 4: 36-9
  3. Butt T, Nadeem A, Mahmood A, Zaidi S. Ciprofloxacin treatment failure in typhoid fever case, Pakistan. Emerging Infect Dis 2003; 9:1621-22
  4. Thretfall EJ, Ward LR. Decreased susceptibility to ciprofloxacin in Salmonella enterlca serotype Typhi, United Kingdom. Emerg Infect Dis 2001; 7:448-50
  5. Hakanen A, Kotilainen P, Huovinen P, Helenius H, Siitonen A. Reduced fluoroquinolone susceptibility in Salmonella enterica serotypes in travelers returning "from Southeast Asia. Emerg Infect Dis 2001; 7: 996-1003
  6. Shakespeare WA, Davie D, Tonnerre C, Rubin MA, Strong M, Petti CA. Nalidixic acid resistant Salmonella enterica serotype typhi presenting as a primary psoas abcess: case report and review of the literature. J Clin Microbiol 2005; 43: 996-8
  7. Aerestrup FM, Wiuff C, Kare M, Threlfall EJ. Letters to the Editor: Is it time to change fluoroquinolone breakpoints for Salmonella spp.? Antlmicrob Agents Chemother 2003; 47: 827-9
  8. Hirose K, Tamura K, Watanabe H. Screening method for Salmonella enterica serotype typhi and serovar paratyphi A with reduced susceptibility to fluoroquinolones by PCR-restriction fragmant length polymorphism. Microbiol Immunol 2003; 47:161-5
  9. Crump JA, Barrett TJ, Nelson JT, Angulo FJ. Reevaluating fluoroquinolone breakpoints for Salmonella enterica serotype typhi and non-typhi salmonellae. Clin Infect Dis 2003; 37: 75-81
  10. Giraud E, Cloeckaert A, baucheron S, Mouline C, Dancla EC. Fitness cost of fluoroquinolone resistance in Salmonella enterica serotype typhimurium. J Med Microbiol 2003; 52: 697-703
  11. Guerra B, Malorny B, Schroeter A, Helmuth R. Multiple resistance mechanisms in fluoroquinolone resistant Salmonella isolates from Germany. Antimicrob Agents Chemother 2003; 47: 2059
  12. Poutanen SM, Low DE. Is it time to change fluoroquinolone MIC breakpoints for Salmonella spp.? Clin Microbiol Newslett 2003; 25: 97-102
  13. Madhulika U, Harish BN, Parija SC. Current pattern in antimicrobial susceptibility of Salmonella typhi isolates in Pondichery. Indian J Med Res 2004;111-4